羅建軍,賴禎平,韋榮耀,鄧亨平,吳龍飛
(四川巴中市中心醫(yī)院心血管內(nèi)科,636001)
·論著·
冠狀動(dòng)脈介入干預(yù)對(duì)患者血流動(dòng)力學(xué)及血清炎性因子水平的影響
羅建軍,賴禎平,韋榮耀,鄧亨平,吳龍飛
(四川巴中市中心醫(yī)院心血管內(nèi)科,636001)
[摘要]目的分析冠狀動(dòng)脈介入干預(yù)對(duì)患者血流動(dòng)力學(xué)及血清炎性因子水平的影響。方法選取76例冠心病患者,依據(jù)患者接受的介入操作不同分為觀察組(PCI術(shù))41例,對(duì)照組(常規(guī)冠狀動(dòng)脈造影檢查)35例。比較兩組患者介入手術(shù)相關(guān)資料,包括:造影劑使用量、校正的TIMI幀數(shù)(CTFC)、平均動(dòng)脈壓等;比較兩組患者術(shù)后24 h血清炎性因子指標(biāo);分析觀察組患者術(shù)后CTFC與白介素-6(IL-6)及金屬蛋白酶-9(MMP-9)的相關(guān)性。結(jié)果觀察組患者造影劑使用量顯著高于對(duì)照組(t=6.371,P<0.01);觀察組術(shù)后校正的TIMI幀數(shù)(CTFC)顯著高于對(duì)照組(t=4.937,P<0.01);觀察組術(shù)后平均動(dòng)脈壓水平顯著高于對(duì)照組(t=4.499,P<0.01)。觀察組患者術(shù)后24 h血清IL-6顯著高于對(duì)照組(t=3.031,P<0.01);觀察組術(shù)后25 h血清MMP-9顯著高于對(duì)照組(t=3.920,P<0.01)。相關(guān)性分析顯示,觀察組患者術(shù)后血清IL-6水平與術(shù)后CTFC呈現(xiàn)顯著正相關(guān)(r=0.700,P<0.01);觀察組患者術(shù)后血清MMP-9水平與術(shù)后CTFC水平呈現(xiàn)正相關(guān),差異有統(tǒng)計(jì)學(xué)意義(r=0.738,P<0.01)。結(jié)論P(yáng)CI術(shù)可導(dǎo)致患者血清炎性因子水平升高,且與冠脈血流呈現(xiàn)負(fù)相關(guān)。
[關(guān)鍵詞]血管成形術(shù);冠心?。?血流動(dòng)力學(xué);細(xì)胞因子類
Effect of percutaneous coronary intervention on blood flow dynamics and serum cytokines of patientsLuoJianjun,NaiZhenping,WeiRongyao,DengHenping,WuLongfei(DepartmentofCardiology,BazhongCentralHospital,Bazhong636001,China)
[Abstract]ObjectiveTo analyze the effect of percutaneous coronary intervention (PCI) on blood flow dynamics and serum cytokines of patients.MethodsSeventy-six patients with coronary heart disease were divided into observation ( PCI,n=41) and control (coronary angiography,n=35 ) groups .ResultsThe contrast agent usage of observation group was significantly higher than control group (t=6.371,P<0.01).The mean arterial pressure and CTFC were significantly higher than those in control group(P<0.01).The levels of serum IL-6 at 24 hours postoperatively and MMP-9 at 25 hours postoperatively were significantly higher than those in control group (P<0.01).The correlation analysis showed that serum IL-6 and MMP-9 were positly associated with CTFC of postoperation (P<0.01).ConclusionPCI can cause serum cytokines increased,which was negative associated with coronary blood flow in CHD patients.
[Key words]Angioplasty;Coronary disease;Hemodynamics;Cytokines
隨著微創(chuàng)外科的發(fā)展,冠脈介入治療(PCI)被用于冠心病的治療[1-2]。多年的臨床驗(yàn)證,PCI具有良好的臨床效果[3-4]。但事實(shí)上,并不是所有接受PCI治療的患者均獲得了滿意的療效。PCI術(shù)后再灌注慢甚至是無(wú)復(fù)流均導(dǎo)致患者治療失敗[5]。導(dǎo)致以上事件的原因很多,其中PCI操作本身導(dǎo)致的全身性應(yīng)激反應(yīng)可能是原因之一[6-9]。因此,我們?cè)O(shè)計(jì)此研究分析冠脈介入干預(yù)對(duì)患者血流動(dòng)力學(xué)及血清細(xì)胞炎性因子水平的影響,以期為此類患者的診療提供參考。
1資料與方法
1.1臨床資料分析2009年1月至2014年1月在我院接受治療的76例冠心病患者的臨床資料。所有患者均經(jīng)臨床及冠狀動(dòng)脈造影檢查明確診斷為冠心病。排除以下情況:合并嚴(yán)重肝腎功能障礙;合并惡性腫瘤等終末期疾??;合并凝血功能障礙;近3個(gè)月發(fā)生過(guò)心肌梗死等心血管事件。依據(jù)患者接受的介入操作不同分為觀察組(PCI術(shù))和對(duì)照組(常規(guī)冠狀動(dòng)脈造影檢查)。本研究共納入研究對(duì)象76例,其中觀察組41例,對(duì)照組35例。兩組患者在性別、年齡、體質(zhì)量指數(shù)(BMI)、心率、空腹血糖值、高血脂病史、吸煙及飲酒史上比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),具有可比性。
1.2治療及檢測(cè) 兩組患者的介入操作均在同一醫(yī)療小組完成。冠脈造影評(píng)價(jià)應(yīng)用定量冠狀動(dòng)脈造系統(tǒng)。兩組患者于術(shù)后24 h采集靜脈血5 mL,采用酶聯(lián)免疫吸附法(ELISA)檢測(cè)以下指標(biāo),包括:白介素-6(IL-6)、白介素-10(IL-10)、超敏C反應(yīng)蛋白(hs-CRP)及金屬蛋白酶-9(MMP-9),試劑購(gòu)置于Abcam公司。
1.3觀察指標(biāo)比較兩組患者一般臨床資料;比較兩組患者介入手術(shù)相關(guān)資料,包括:造影劑使用量、校正的TIMI幀數(shù)(CTFC)、平均動(dòng)脈壓等;比較兩組患者術(shù)后24 h血清炎性因子指標(biāo);分析觀察組患者術(shù)后CTFC與IL-6及MMP-9的相關(guān)性。
1.4統(tǒng)計(jì)學(xué)處理采用SPSS19.0軟件進(jìn)行統(tǒng)計(jì)分析。計(jì)量資料比較采用非配對(duì)t檢驗(yàn)。率的比較使用χ2檢驗(yàn),相關(guān)性分析采用Pearson相關(guān)性檢驗(yàn)。P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2結(jié)果
2.1介入手術(shù)相關(guān)資料 見(jiàn)表1。
2.2術(shù)后24h血清炎性因子水平觀察組患者術(shù)后24h血清IL-6顯著高于對(duì)照組(t=3.031,P<0.01);觀察組術(shù)后24 h血清MMP-9顯著高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(t=3.920,P<0.01),見(jiàn)表2。
表1 兩組患者介入手術(shù)相關(guān)資料
表2 兩組患者術(shù)后24 h血清炎性因子水平的比較±s)
2.3觀察組患者術(shù)后CTFC與IL-6及MMP-9的相關(guān)性分析 如圖1所示,觀察組患者術(shù)后血清IL-6水平與術(shù)后CTFC呈現(xiàn)顯著正相關(guān)(r=0.700,P<0.01);觀察組患者術(shù)后血清MMP-9水平與術(shù)后CTFC水平呈現(xiàn)正相關(guān),差異有統(tǒng)計(jì)學(xué)意義(r=0.738,P<0.01)。
3討論
我們的研究顯示,雖然兩組患者在穿刺路徑及術(shù)后左室射血分?jǐn)?shù)上比較差異均無(wú)統(tǒng)計(jì)學(xué)意義。但觀察組患者造影劑使用量顯著高于對(duì)照組,且觀察組術(shù)后CTFC值及術(shù)后平均動(dòng)脈壓水平顯著高于對(duì)照組。這提示PCI一定程度影響了患者血流動(dòng)力學(xué)的穩(wěn)定。在血清炎性因子水平的分析中,我們發(fā)現(xiàn)兩組患者術(shù)后24 h血清IL-10及hs-CRP水平比較差異均無(wú)統(tǒng)計(jì)學(xué)意義。但觀察組患者術(shù)后24 h血清IL-6及血清MMP-9顯著高于對(duì)照組。在炎癥過(guò)程中,MMP主要由巨噬細(xì)胞分泌,其功能多樣,其參與動(dòng)脈粥樣斑塊的形成;促進(jìn)血管平滑肌的增殖、遷移等[10]。同時(shí)MMP還是導(dǎo)致動(dòng)脈粥樣斑塊不穩(wěn)定的因素之一,過(guò)高水平的MMP可分解斑塊表面纖維帽,使得斑塊容易破裂[11]。IL-6是免疫調(diào)節(jié)中的重要細(xì)胞因子,其可同時(shí)影響細(xì)胞免疫和體液免疫,是機(jī)體抗組織損傷及感染的重要炎性因子。PCI手術(shù)操作對(duì)血管內(nèi)皮細(xì)胞的損傷可能是導(dǎo)致IL-6水平升高的原因之一。而IL-6可刺激巨噬細(xì)胞活動(dòng),可促進(jìn)MMP的合成和分泌,這會(huì)導(dǎo)致動(dòng)脈粥樣斑塊不穩(wěn)定性增加,可能是血清促炎因子水平升高對(duì)PCI預(yù)后不良的影響機(jī)制[10]。CTFC是評(píng)估PCI術(shù)后冠脈血流恢復(fù)的重要指標(biāo)。我們分析了CTFC與IL-6及MMP-9的相關(guān)性發(fā)現(xiàn),術(shù)后血清IL-6及MMP-9水平均與術(shù)后CTFC呈現(xiàn)顯著正相關(guān)。這提示血清炎性因子水平的升高與PCI術(shù)后冠脈血流之間存在一定聯(lián)系,但具體機(jī)制尚需進(jìn)一步研究。
綜上,我們的研究顯示PCI術(shù)可導(dǎo)致患者血清炎性因子水平升高,且與冠脈血流呈現(xiàn)負(fù)相關(guān)。
(本文圖1見(jiàn)插圖4-2)
參考文獻(xiàn)
[1]Kimura S,Inagaki H,Haraguchi G,et al.Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction[J].Circ J,2014,78(1):159-169.
[2]Gupta MD,Girish MP,Subhendu MS,et al.Percutaneous coronary intervention of all three coronary arteries originating from single coronary artery arising from the right sinus[J].Cardiovasc Interv Ther,2013,28(3):322-326.
[3]覃雙林.冠心病患者冠狀動(dòng)脈病變嚴(yán)重程度與冠心病危險(xiǎn)因素的相關(guān)分析[J].心血管病防治知識(shí):下半月,2014,(11):57-59.
[4]祝小霞,丁旵東,曾勝煌,等.冠狀動(dòng)脈狹窄程度與冠心病危險(xiǎn)因素的相關(guān)性分析[J].中華老年心腦血管病雜志,2014,16(3):267-270.
[5]Balin M,Celik A,Kobat MA,et al.Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI[J].J Thromb Thrombolysis,2012,34(4):483-490.
[6]Ndrepepa G,Tada T,Fusaro M,et al.Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease[J].Clin Res Cardiol,2012,101(12):1003-1011.
[7]Higuchi Y,Hiro T,Takayama T,et al.Impact of coronary plaque burden and composition on periprocedural myocardial infarction and coronary flow reserve after percutaneous coronary intervention[J].Int Heart J,2014,55(5):391-396.
[8]Akdeniz C,Umman S,Kaplan A,et al.Coronary plaque composition and post-PCI complications in NSTEMI[J].JACC Cardiovasc Imaging,2013,6(12):1349-1350.
[9]Sato T,Kameyama T,Noto T,et al.Impaired macrophage production of anti-atherosclerotic interleukin-10 induced by coronary intraplaque hemorrhage in patients with acute coronary syndrome and hyperglycemia[J].J Diabetes Complications,2014,28(2):196-202.
[10] Tanindi A,Sahinarslan A,Elbeg S,et al.Association of matrix metalloproteinase-1,matrix metalloproteinase-9,tissue inhibitor of matrix metalloproteinase-1,and interleukin-6 with epicardial and myocardial perfusion[J].Coron Artery Dis,2011,22(4):253-258.
[11] Robertson L,Grip L,Mattsson HL,et al.Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention[J].J Intern Med,2007,262(6):659-667.
(收稿日期:2015-04-10)
作者簡(jiǎn)介:羅建軍,副主任醫(yī)師,Email:13981687998@qq.com
中圖分類號(hào):R541.4
文獻(xiàn)標(biāo)識(shí)碼:A
DOI:10.3969/J.issn.1672-6790.2015.04.019